3 月末开放式理财产品达基率上升——银 行理财月度跟踪（2025.03） [Table_ReportType] 行业月报 | [Table_StockAndRank] 银行 | | | --- | --- | | 投资评级 | 看好 | | 上次评级 | 看好 | | [Table_Author] 张晓辉 | 银行业分析师 | 执业编号：S1500523080008 [Table_Industry] 银行 [Table_ReportDate] 2025 年 4 月 10 日 邮 箱：zhangxiaohui@cindasc.com 信达证券股份有限公司 证券研究报告 行业研究 本期内容提要: 1）收益类型：发行理财产品 6191 款，非保本型产品 6191 款，市场占比 100%；2）期限类型：1-3 个月期限产品发行量占比下降。 到期市场情况：3 月最后一周（3.24-3.31）理财产品到期 1735 款： [Table_S [➢Table_Summary 破净及达基率情况： ummary] ] 1）破净率近期波动平缓：截至 3 月底，全市场理财产品破净率为 2.49%， 环比下降 1.67 个百分点；2） ...

Investment Rating - The investment rating for the banking industry is "Positive" [2] Core Insights - The report highlights a recent increase in the proportion of open-ended wealth management products, with the closed-end product reach rate at 81.59% and the open-end product reach rate at 55.50% as of the end of March 2025 [3][16][17] - The overall market's wealth management product break-even rate is 2.49%, showing a decrease of 1.67 percentage points compared to the previous month [3][13] Summary by Sections 1. Wealth Management Market Overview - The break-even rate for wealth management products as of March 2025 is 2.49%, down from a peak of 20.60% in December 2022 [13] - The reach rate for closed-end wealth management products is 81.59%, while the open-end products have a reach rate of 55.50% [16][17] 2. Net Value Wealth Management Products Tracking - The number of existing net value wealth management products decreased to 19,000 as of March 2025, a decline of 1.67% from the previous month [4][24] - The proportion of fixed-income products among net value products is 91.78% [30] 3. Issuance Market Situation - In March 2025, the total number of newly issued wealth management products was 6,191, representing a year-on-year increase of approximately 46.95% [40] - Non-principal guaranteed wealth management products have seen a significant rise, while principal guaranteed products have nearly disappeared [43] 4. Wealth Management Yield Situation - As of March 31, 2025, the expected annualized yields for 3-month, 6-month, and 1-year wealth management products are 2.34%, 2.71%, and 3.03%, respectively [5] - The yield for 1-year wealth management products from city commercial banks has increased compared to the previous month [15] 5. Investment Recommendations - The report suggests focusing on national banks with solid fundamentals and low valuations, such as Postal Savings Bank, Agricultural Bank, and CITIC Bank, particularly in the context of state-owned enterprise reforms [8] - It also highlights regional banks like Qilu Bank and Ningbo Bank that are expected to perform well due to ongoing recovery in small and micro enterprises [8]

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 万孚生物(300482) | 上次评级 | 买入 | | --- | --- | | 投资评级 | 买入 | [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 夯实产品竞争力，业务实现高质量增长 盈利能力持续增强，多元化布局助力高 质量增长 新冠基数已消化，国际市场渐入收获期 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 境外业务快速发展，盈利能力稳中有升 [Table_ReportDate] 2025 年 04 月 10 日 [Table_S 事件：ummar 公司发布y] 2024 年年报，2024 年实现 ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 澳华内镜(688212) 投资评级 上次评级 [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 毛利率稳定，招标恢复后收入增速有 望回升 积极调控疫情实现营收，研投助力多 元布局 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 利润短期承压，静待招采恢复后收入增速回升 [Table_ReportDate] 2025 年 04 月 10 日 | [Table_Profit] 重要财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | -- ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 澳华内镜(688212) 投资评级 上次评级 [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 毛利率稳定，招标恢复后收入增速有 望回升 积极调控疫情实现营收，研投助力多 元布局 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 利润短期承压，静待招采恢复后收入增速回升 [Table_ReportDate] 2025 年 04 月 10 日 [Table_S 事 件 ：ummar 公 司 发 布y] 2024 年年报， 2024 年 实 现 营 业 收 入 7.50 亿 元 （yoy+10.54%），归母净利润 0 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company achieved a revenue of 3.065 billion yuan in 2024, representing a year-on-year growth of 10.85%, with a net profit of 562 million yuan, up 15.18% year-on-year [1] - The overseas business is rapidly developing, with a 43% increase in foreign revenue driven by localized operations in developing countries and FDA EUA authorization for respiratory products in North America [2] - The company's diversified business lines show strong growth resilience, with significant contributions from chronic disease management and infectious disease testing [2] - Profitability is steadily improving due to optimized revenue structure and cost control, with a gross margin of 64.15% in 2024, up 1.54 percentage points year-on-year [2] - The company is expected to achieve revenues of 3.476 billion, 3.980 billion, and 4.554 billion yuan from 2025 to 2027, with corresponding net profits of 642 million, 746 million, and 877 million yuan, reflecting growth rates of 14.3%, 16.3%, and 17.5% respectively [2] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 3.065 billion yuan, a 10.85% increase from the previous year, and a net profit of 562 million yuan, marking a 15.18% increase [3] - The gross margin for 2024 was 64.15%, an increase of 1.54 percentage points year-on-year, while the overall net profit margin reached 18.44%, up 0.81 percentage points [2][3] Revenue Breakdown - Domestic revenue was 1.962 billion yuan, down 1.65% year-on-year, while overseas revenue reached 1.103 billion yuan, up 43.23% year-on-year [2] - The chronic disease management testing business generated 1.369 billion yuan, a 22.38% increase, while the infectious disease testing business brought in 1.042 billion yuan, up 9.50% [2] Future Projections - Revenue projections for 2025, 2026, and 2027 are 3.476 billion, 3.980 billion, and 4.554 billion yuan, with year-on-year growth rates of 13.4%, 14.5%, and 14.4% respectively [2][3] - Expected net profits for the same years are 642 million, 746 million, and 877 million yuan, with growth rates of 14.3%, 16.3%, and 17.5% [2][3]

Investment Rating - The investment rating for Yanzhou Coal Mining Company is "Buy" [3] Core Views - The acquisition of a 51% stake in Northwest Mining Company for CNY 14.066 billion is a strategic move to enhance growth and resource base [3][4] - Northwest Mining has rich coal resource reserves with a total approved capacity of 61.05 million tons per year, and it operates in key regions such as Shaanxi, Gansu, Shanxi, and southern Inner Mongolia [3] - The company is expected to see a rebound in profitability in 2024, excluding non-recurring losses, with an adjusted net profit of approximately CNY 2.4 billion, indicating growth compared to 2023 [3] - The acquisition is projected to increase Yanzhou Coal's revenue and net profit by approximately 12.37% and 7.68% respectively in 2024 [4] - The deal is characterized by low cash outflow and attractive valuation metrics, with a price-to-earnings ratio of 7.69, which is lower than Yanzhou Coal's A-share PE of 8.8 [6] Financial Summary - For 2023, total revenue is reported at CNY 150.1 billion, with a projected decline to CNY 139.1 billion in 2024, followed by a slight recovery in subsequent years [5] - The net profit attributable to the parent company is expected to decrease from CNY 20.1 billion in 2023 to CNY 14.4 billion in 2024, with a gradual recovery thereafter [5] - The gross margin is forecasted to decline from 40.6% in 2023 to 35.8% in 2024, stabilizing around 34% in the following years [5] - The company aims to achieve a coal production target of 300 million tons, with the acquisition being a crucial step towards this goal [4][6]

[Table_ReportType] 公司点评报告 证券研究报告 公司研究 [Table_StockAndRank] 仙鹤股份(603733) | 投资评级 | 买入 | | --- | --- | | 上次评级 | 买入 | [Table_Title] 仙鹤股份：控股股东大额增持，成本改善+销 量增量+新产品开发 [Table_ReportDate] 2025 年 04 月 09 日 报告内容摘要: [Table_S 事件：公司控股股东仙鹤集团计划自 ummary] 4 月 7 日起 6 个月内，累计拟增持股份金 额 3-5 亿元，彰显发展信心和投资价值。 浆纸价格小幅探涨，成本改善明确。我们预计 Q1 公司盈利有望环比平稳或小 幅改善，Q2 有望创新高，全年盈利有望超预期。 1）浆纸价格小幅提升：我们预计 2-3 月热转印、热敏、格拉辛、食品卡等景气 向上纸种提价部分落地，且 4 月仍有提价预期；4 月浆厂坚持挺价（阔叶+20 美金/吨）、以涨促销，后续浆价或震荡偏强，驱动盈利能力提升。 2）新基地成本改善：公司广西基地、湖北基地林浆纸一体化匹配度逐步提高， 伴随新基地产能爬坡，我们预计盈利中枢持续向上。 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The controlling shareholder, Xianhe Group, plans to increase its shareholding by 300-500 million yuan over the next six months, demonstrating confidence in the company's development and investment value [1] - The price of pulp paper has slightly increased, leading to improved cost structures. The company is expected to see stable or slightly improved profits in Q1, with Q2 potentially reaching new highs, and annual profits expected to exceed forecasts [2][3] Summary by Sections Pulp Price and Cost Improvement - Pulp prices are expected to rise due to price increases in various paper types, with further price hikes anticipated in April. The company is expected to benefit from improved profitability as pulp prices stabilize [2] - The integration of the new bases in Guangxi and Hubei is expected to enhance cost efficiency, with profitability expected to trend upwards as production ramps up [2] Growth Path and Expansion - The company is expanding its production capacity with new bases in Guangxi and Hubei, projected to produce over 900,000 tons of paper and pulp. This is expected to drive a paper production growth rate of over 30% in 2025 [3] - Continuous development of differentiated products, including various specialized papers, is underway, which will enhance the product portfolio [3] - The company aims to expand its overseas business, gradually increasing the proportion of overseas revenue and leveraging international production capacity for accelerated growth [3] Financial Projections - The projected net profits for 2024-2026 are 1.06 billion, 1.44 billion, and 1.79 billion yuan, respectively, with corresponding PE ratios of 13.5X, 10.0X, and 8.0X, maintaining a "Buy" rating [3][4]

Investment Rating - The investment rating for Yanzhou Coal Mining Company is "Buy" [3] Core Views - The acquisition of a 51% stake in Northwest Mining Company for 14.066 billion yuan is a strategic move to enhance growth and resource reserves [3][4] - Northwest Mining has rich coal resource reserves with a total approved capacity of 61.05 million tons per year, and it operates in key regions such as Shaanxi, Gansu, Shanxi, and southern Inner Mongolia [3] - The company is expected to see a growth in profitability in 2024, excluding non-recurring losses, with an adjusted net profit of approximately 2.4 billion yuan [3] - The acquisition is projected to increase Yanzhou Coal's revenue and net profit by approximately 12.37% and 7.68% respectively in 2024 [4] Financial Summary - In 2023, total revenue was 150.1 billion yuan, with a projected decline to 139.1 billion yuan in 2024, followed by a slight recovery in subsequent years [5] - The net profit attributable to the parent company is expected to decrease from 20.1 billion yuan in 2023 to 14.4 billion yuan in 2024, with a gradual recovery thereafter [5] - The gross margin is projected to decline from 40.6% in 2023 to 35.8% in 2024, reflecting the impact of market conditions [5] - The company is expected to maintain a low P/E ratio of 9.59 in 2025, indicating potential undervaluation [5][6] Strategic Focus - Yanzhou Coal will continue to focus on its coal business and accelerate the implementation of its goal to reach 300 million tons of raw coal production [6] - The acquisition is seen as a key step towards achieving this production target and enhancing the company's profitability [4][6] - The company plans to actively seek high-quality coal resources in strategic energy bases such as Shaanxi, Inner Mongolia, and Xinjiang, while also exploring overseas acquisition opportunities [6]